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Abstract
Background: Traumatic brain injury (TBI) is a devastating condition with significant long-term mortality and
morbidity. Despite current need for objective indicators to guide initial decision-making, few reliable acute phase
prognostic factors have been identified. Early magnetic resonance imaging (MRI) has been investigated as a
prognostic tool, but uncertainty remains in both its discriminative predictive value and which acute phase lesion
patterns correlate with long-term outcome.
Methods: We will conduct a systematic review of observational cohort studies and randomized controlled trials of
adult moderate or severe TBI patients who underwent MRI in the acute phase after trauma. A high sensitivity search
strategy will be employed in MEDLINE, EMBASE, BIOSIS, and Cochrane CENTRAL to identify citations. Two reviewers
will independently screen all identified references for eligibility and extract data into a standardized form. Data will
be collected on study design, baseline demographics, trauma characteristics, magnetic resonance (MR) technical
specifications, lesion patterns, and outcomes as related to acute MRI imaging. If meta-analysis is possible,
quantitative data for each outcome will be pooled per type of lesion pattern using random effects models and
expressed as Mantel-Haenszel relative risks in order to determine the prognostic value of lesions detected on
acute MRI and their strength as discriminatory predictors of long-term outcome. Statistical heterogeneity will be
evaluated with the I2 statistics, and risk of bias and reporting quality will be assessed with standardized scales.
Subgroup analyses are planned as a function of TBI severity, MRI-timing post-TBI, MRI field strength, MRI sequence,
timing of outcome assessment, and risk of bias.
Discussion: We expect significant clinical heterogeneity, as eligible studies will likely encompass different periods in
evolving MRI technology in addition to significant variability of image sequence protocols and timing of acquisition
between centers. Based on existing studies in TBI, we expect lesions detected in the brainstem to be of significant
predictive value as MRI is particularly sensitive for imaging the brain’s posterior fossa. Our systematic review will
allow clinicians to more accurately interpret MRI in the context of determining prognosis for moderate and severe
TBI patients and inform researchers in this domain to improve the methodology of future studies.
Systematic review registration: Prospero CRD42015017074
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Background
Traumatic brain injury (TBI) is a significant global
health problem, with the 1.7 million cases occurring
annually representing upwards of $60 billion of direct
and indirect health care costs in the USA alone [1, 2].
Moderate and severe TBI are most often life-threatening
conditions requiring immediate intensive care. The deter-
mination of long-term neurological prognosis is thus of
importance as it may inform patients or their represen-
tatives and better guide critical level of intervention
decision-making [3]. Few reliable prognostic factors cur-
rently exist in this domain, with the large-scale IMPACT
study identifying only age, pupillary reactivity, and the
motor subscale of the Glasgow Coma Scale (GCS) as inde-
pendent predictors of outcome [4, 5]. Recently, certain
biomarkers [6] have also shown promise as outcome indi-
cators; however, none of these factors are presently appro-
priate for clinical use.
Computed tomography (CT) currently plays a pivotal
role in the immediate post-injury work-up where gross
lesion characterization and indications for urgent surgi-
cal intervention must be rapidly established [7]. In the
last four decades, magnetic resonance imaging (MRI)
has emerged as a highly sensitive imaging tool in TBI.
Its superiority compared to CT in detecting cerebral
lesions in TBI, particularly non-hemorrhagic lesions and
lesions localized to the posterior fossa, became evident
just a few years following its clinical availability [8].
Visualization of the brainstem is especially crucial as a
large volume of evidence from animal [9] and histological
[10] studies have demonstrated that deeper, more caudally
located lesions are correlated with greater severity of
trauma. In continuity with this centripetal model [9] of
brain injury, it has been proposed that such deeper lesions
also have a greater significance on long-term outcome and
may serve as prognostic indicators [11, 12]. Though sev-
eral setbacks such as long imaging times and incompati-
bility of metallic objects have limited its use, advances in
magnetic resonance technology are rapidly overcoming
these obstacles giving MRI a growing role in the acute
phase evaluation of TBI.
Over the last several decades, numerous studies have
investigated the predictive value of MRI lesions. Owing
at least in part to the diversity of approaches possible in
interpreting cerebral lesions induced by TBI and corre-
lating them to unfavorable long-term outcome, the results
of such studies have been variable to date and at times
contradictory. We seek to systematically identify all stud-
ies in this domain and to methodically synthesize their
data studying MRI as a prognosticator in moderate and
severe TBI. Our primary objective is to determine the
prognostic value of MRI in TBI by identifying the lesion
patterns that significantly correlate with mortality and
neurological outcome. We also seek to investigate sources
of possible heterogeneity and evaluate the methodological
quality of the included studies.
Methods
Design
A team of experts including intensivists, internists, epi-
demiologists, and a biostatistician collaborated to de-
velop the research question and study design of this
systematic review, in accordance with the methodo-
logical guidelines delineated in the Cochrane Handbook
for Systematic Reviews and Meta-Analyses [13]. This
protocol was registered in PROSPERO (http://www.crd.york.
ac.uk/PROSPERO/display_record.asp?ID=CRD42015017074)
CRD42015017074. The final manuscript will be written
in accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) rec-
ommendations [14].
Information sources and search strategy
MEDLINE, EMBASE, BIOSIS, and the Cochrane Central
Register of Controlled Trials (CENTRAL) will be system-
atically searched from their inception, with an update
planned before submission for publication. A three-
pronged search strategy maximizing sensitivity has been
developed to identify studies investigating MRI as a prog-
nostic tool in TBI. Free text keywords, as well as Medical
Subject Heading (MeSH) and Emtree terms, linked with
the Boolean operator “OR” were used to design each
prong of the search strategy, with the three prongs linked
with the operator “AND.” All strategies will be reviewed
by an information specialist (health care librarian) for
robustness. After selection is complete, the reference lists
of included studies will be reviewed to identify any add-
itional eligible studies. An example of our search strategy
is provided (Additional file 1).
Eligibility criteria and study selection
The following inclusion criteria will be utilized to deter-
mine study eligibility: (1) cohort studies and randomized
controlled trials (2) investigating the prognostic value of
standard structural MRI (3) performed in the acute
phase (≤28 days post-trauma) (4) of moderate or severe
TBI (≥50 % with GCS ≤12) (5) in an adult population
(≥80 % of patients aged ≥18 years old) (6) reporting at
least one of our outcome measures of interest (mortality,
Glasgow Outcome Scale (GOS), or extended Glasgow
Outcome Scale (GOSe) as defined below). Studies with a
significant population (>10 %) of penetrating TBI will be
excluded. There will be no restriction based on publica-
tion date or language; translators will be consulted for ar-
ticles published in languages other than English or French.
Two blinded reviewers will perform screening for
study eligibility independently in a two-step process. Re-
trieved citations will initially be screened by title and
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abstract review for potential eligibility; retained studies
will then be assessed by full-text analysis to confirm in-
clusion in the systematic review. A third reviewer will be
consulted for arbitration in case of discordance. Reasons
for exclusion at the full-text stage will be recorded and
presented for transparency.
Data collection
Two reviewers will independently extract data into a
standardized data abstraction form, with a third to be
consulted in cases of discordance. The following set of
data will be extracted from each study: (1) study design,
such as year, setting, study type, sample size, duration of
follow-up, inclusion and exclusion criteria, sources of
funding, and conflicts of interest; (2) patient characteris-
tics, such as age, sex, comorbidities, and mechanism of
injury; (3) therapeutic and supportive measures, such as
use of mechanical ventilation, intracranial drains, and
surgical intervention; (4) characteristics of the magnetic
resonance imaging modality, such as time to scan, field
strength, brand, sequences taken, and image plane; and
(5) measures of outcome presented in relation to MRI
image characteristics, such as lesion localization, lesion
type, lesion size, and radiological scores, stratified by
image sequence when possible. The initial data abstraction
form will be piloted on five studies to ensure robustness,
with subsequent modifications for thoroughness if
necessary.
To avoid duplication, if the same study is published
more than once, either the most complete article will be
retained or all articles will be extracted and presented as
a single study in analyses.
Assessment of methodological quality
The methodological quality of any randomized con-
trolled trials (RCTs) included in this systematic review
will be evaluated with the Cochrane Collaboration’s risk
of bias tool [13]. However, given that this is a prognostic
systematic review and that we predict that the majority
of the studies eligible for this review will have observa-
tional cohort designs, we modified the Quality in Prog-
nostic Studies (QUIPS) tool [15] to develop a 26-item
checklist appropriate for the evaluation of the risk of bias
of such studies (see Additional file 2 for the complete
tool). The QUIPS tool is a validated method for assessing
the risk of bias in prognostic factor studies; we supple-
mented its list of searching questions with excerpts from
the QUADAS-2 tool [16, 17] for additional rigor as we felt
that neither framework alone encompassed all relevant
questions regarding risk of bias. The STROBE statement’s
[18] 22-item checklist will be used to evaluate the report-
ing quality of the included studies. By performing these
assessments independently and in parallel, we seek to dif-
ferentiate between methodological bias and omissions in
reporting in the primary studies. Summaries of these eval-
uations will be presented in a graphical format to offer
precise recommendations for future studies in this domain
and, in the case of the risk of bias assessment, to also
guide subgroup analysis. Both risk of bias and reporting
quality evaluations will be performed independently by
two reviewers.
Quality of evidence
An adaptation of the GRADE framework for prognostic
studies [19] will be employed to judge the quality of evi-
dence for each outcome reported in this systematic
review.
Outcomes
Our primary outcomes will be mortality and unfavorable
long-term Glasgow Outcome Scale (GOS or GOSe),
defined as either a GOS of 1–3 or a GOSe of 1–4. Our
secondary outcomes include duration of hospital stay,
duration of ICU stay, any reported scales employed by
the included studies to determine patient function (such
as the Disability Rating Scale (DRS), the Craig Handicap
Assessment and Rating Technique (CHART), and mini-
mental state examination (MMSE)), and all other possible
clinical end-point measures (such as coma duration, prob-
ability of readmission, and duration of rehabilitation).
Statistical analysis and data synthesis
Data will be presented in a descriptive manner. Nominal
variables and count data will be reported using propor-
tions while continuous variables will be presented as
either means with standard deviations or medians with
ranges, depending on what is reported in the primary
studies. If reported, effect measures will be presented in
both their adjusted forms and unadjusted forms where
possible. The number of studies reporting each type of
lesion pattern in relation to outcome will be reported.
If meta-analysis is possible, random effects models will
be employed. Dichotomous outcomes will be presented
as risk ratios (RR) with accompanying 95 % confidence
intervals (CIs) and forest plots, as generated with the
Mantel-Haenszel method using Cochrane Review Manager
version 5.2 (The Cochrane Collaboration, Copenhagen,
Denmark, 2012). Data from the mortality and GOS will be
presented at hospital discharge, 3, 6, and 12 months or
beyond, according to the availability of the data.
Ordinal data will be presented in tabular format, with
risks and relative risks for each study accompanied by
95 % CIs calculated using exact formulas. P values for
global and trend tests will be computed for each study
using SAS 9.3 (SAS Institute Inc., Cary, NC, USA, 2011).
Ordinal data from radiological scores will also be dichot-
omized, when possible, according to the presence or
absence of brainstem lesions and pooled using the same
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meta-analytical methods for dichotomic data as de-
scribed above.
Heterogeneity will be evaluated by the I2 statistic and
interpreted via the recommended standard categorization
of negligible (<40 %), moderate (30–60 %), substantial
(50–90 %), or considerable (75–100 %) [13]. Where
permitted by the data available, sensitivity and subgroup
analyses will be undertaken to explore sources of hetero-
geneity and test the robustness of the results. Such ana-
lyses will be performed in regard to minimal age of
inclusion, severity of TBI, timing of MRI post-TBI, MRI
field strength, MRI sequence, timing of outcome as-
sessment, inter-rater reproducibility of image analysis,
timing of outcome assessment, rehabilitation strat-
egies, and study risk of bias. Visual analysis of funnel
plots will be used to evaluate the presence and degree
of publication bias.
Discussion
Determination of long-term prognosis is an important
step in the acute evaluation of moderate and severe TBI
patients, particularly since a large proportion of such pa-
tients are young [1] with few or no comorbid conditions.
Although a significant body of evidence has shown that
MRI is superior to CT in detecting most types of
traumatic parenchymal lesions [8, 20], only the latter is
currently routine whereas use of the former remains
sporadic in the acute phase. While the presence of sev-
eral different lesion types, particularly those attaining
the brainstem, has been correlated with severity of
trauma [9, 10], the role of employing sensitive imagery
such as MRI as an early prognosticator is not yet clear.
In TBI patients, doubt remains concerning both the dis-
criminatory ability of early MRI as well as which specific
lesion patterns yield the highest prognostic information.
This project seeks to identify, class, and synthesize all
existing original research with data relating lesions iden-
tified on acute MRI to clinical outcome in moderate and
severe TBI patients. Our proposed systematic review of
prognostic studies is based on well-recognized methodo-
logical [13, 16] and reporting [14] recommendations. It
will determine the lesion patterns and radiological char-
acteristics identifiable on acute MRI that correlate with
the long-term outcome of patients having suffered mod-
erate or severe TBI. By summating all existing evidence
in the domain, the results of this systematic review will
thus seek to conclusively inform clinicians and decision-
makers on the significance, if any, of information pro-
vided by acute MRI in TBI and to explicitly establish its
pertinence in the early management of moderate and se-
vere TBI. Furthermore, by methodically classifying existing
evidence and evaluating its risk of bias, our review
seeks to also inform investigators of future studies in
order to improve consistency in the approach to
image interpretation and establish areas where further
research is required.
Despite our intention to use a rigorous methodology
and to employ a widely accepted statistical model for
data analysis, we expect to likely encounter elevated
clinical and statistical heterogeneity in the majority of
our primary analyses. We anticipate this variability due
to several factors, the most notable being that we expect
that the majority of included studies will be of an obser-
vational cohort design. The pool of eligible studies will
likely also encompass a significant variability in technical
characteristics, due to both the evolution of MRI tech-
nology since its clinical introduction, as well as differ-
ences in sequence protocols and timing of imaging
between study centers. Moreover, the method of image
interpretation and lesion characterization is often vari-
able, making it difficult to compare results across stud-
ies. To address such concerns regarding methodology,
this systematic review will provide a global analysis of
the quality of the evidence through the evaluation of
both the risk of bias and the reporting quality of all the
included studies via standardized assessment tools. The
final resultant of this review will thus be both a system-
atic aggregate of the evidence that exists on the subject
of prognostication in TBI via MRI as well as a critical
appraisal of the methodology employed in this domain
to ultimately also improve the quality of future studies.
Our team plans to disseminate the results of the system-
atic review via presentation at research conferences and
by publishing the results in a peer-reviewed journal.
Additional files
Additional file 1: Example of Medline search strategy. Description: In
this file, we give an example of the Medline search strategy we will use
for this study. (PDF 167 kb)
Additional file 2: Evaluation of risk of bias. Description: Adapted
QUIPS tool with additions from QUADAS-2. (DOCX 35 kb)
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